Toggle navigation
HOME
NEWSFEEDS
Healthcare Industry News
Medical Devices
Biopharmaceuticals
Diagnostics
Cardiology
Interventional
Neuro
Oncology
Orthopaedic
Surgery
People
Distribution
FDA Actions
Regulatory (INTL)
Mergers & Acquisitions
Venture Capital
INDEPENDENT REPS
For MANUFACTURERS:
Find Reps NOW
Post Your Rep Opportunity
Not sure? Let us help!
For REPS and DISTRIBUTORS:
Not in FindReps? Contact us!
ISR REGISTRY:
Independent Sales Reps - USA
Not a MEMBER Yet?
Join HSMN
FORUMS
Independent Sales Reps & Distributors
The Network Bulletin Board
Getting Started in Medical Sales
Show All Forums
RESOURCES
FindReps®
Help / FAQs
INDUSTRY LINKS:
Medical Device Companies
Biopharmaceutical Companies
Professional Organizations
Government & Regulatory
Products & Services
Venture Capital
MEMBERS
Join HSMN
Forgot Username / Password
Help / FAQs
PASSWORD REQUIRED:
Company Links Listing (Manufacturers)
Products & Services Listing (Vendors)
Post in Forums
Renew Membership
Change Password
Update Contact Info
Something else? - Contact Us
ABOUT
About HSMN
Membership Info
FindReps®
Join HSMN
Help / FAQs
Submit News Release
Info for Advertisers
Contact Us
Searching News Database:
Fanapt
HSMN NewsFeed - 21 Jul 2017
Vanda Receives Negative Opinion for Marketing Authorization from the European Medicines Agency on Fanaptum(TM) for the Treatment of Schizophrenia
Biopharmaceuticals
Regulatory
HSMN NewsFeed - 8 Dec 2016
Vanda Pharmaceuticals Settles Fanapt(R) Patent Litigation with Apotex
Biopharmaceuticals
Generics
Litigation
Licensing
HSMN NewsFeed - 8 Mar 2011
Vanda Pharmaceuticals Receives Orphan Drug Designation in Europe for tasimelteon
Biopharmaceuticals
Regulatory
HSMN NewsFeed - 11 Jan 2010
Novartis Launches Schizophrenia Treatment Fanapt in the US, Offering Patients an Attractive Alternative to Existing Medications
Biopharmaceuticals
HSMN NewsFeed - 12 Oct 2009
Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
Biopharmaceuticals
Licensing
HSMN NewsFeed - 12 Oct 2009
Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt(TM) in the U.S. and Canada for the Treatment of Schizophrenia
Biopharmaceuticals
Licensing
HSMN NewsFeed - 7 May 2009
Vanda Pharmaceuticals Announces Withdrawal of Director Nominees and Proposal to Liquidate Submitted by Tang Capital
Biopharmaceuticals
Return to NewsFeed
